Displaying 1 - 10 of 12 for Cancer - Head/Neck
  • Advanced Head and Neck Cancer Treatment (H-32972)
    • This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with cetuximab in treating patients who have undergone surgery for locally advanced head and neck cancer.
  • Advanced Nasopharyngeal Carcinoma Phase 3 Study (H-37526)
    • This Phase III trial is to assess if combined gemcitabine-carboplatin (GC) followed by adoptive T-cell therapy would improve clinical outcome for patients with advanced nasopharyngeal carcinoma (NPC).
  • Biospecimen Banking (H-37203)
    • This study obtains samples from HIV-positive and negative patients with HPV-related cancers of the oropharynx, cervix and anus.
  • Head and Neck Cancer Biospecimen Collection Pilot Project (H-36565)
    • The purpose of this research is to discover genetic changes associated with cancer by documenting the changes that occur to the DNA, RNA and proteins found in head and neck cancer cells.
  • Head and Neck Specimens Collection (H-35705)
    • This study collects, stores and uses tissue samples including blood, tumor and biopsy samples in a biobank.
  • Head and Neck Squamous Cell Carcinoma Study (H-39773)
    • The purpose of this research is to see whether metformin can improve the response rate in patients undergoing chemotherapy and radiation for squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx.
  • HPV-Related Cancer Study (H-36021)
    • The purpose of this study is to find the biggest dose of HPVSTs that is safe, to see how long they last in the body, to learn what the side effects are and to see if the HPVSTs will help people with HPV associated cancers.
  • Improving Self-Management in Head and Neck Cancer (H-38984)
    • The purpose of this study is to evaluate a program that we have developed for head and neck cancer patients and their partners.
  • NexTSTEPS Study (H-39002)
    • The purpose of this study is to evaluate a program that we have developed for advanced cancer patients and their family caregivers.
  • REGN2810 Study (H-38961)
    • This is a phase 1, open-label, multicenter, ascending-dose escalation study of REGN2810, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.